View in EDS

Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.

Saved in:
Bibliographic Details
Title: Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
Authors: Banerjee S; Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK., Oza AM; Princess Margaret Hospital, Toronto, Canada., Birrer MJ; Massachusetts General Hospital, Boston, USA; Harvard Medical School, Boston, USA., Hamilton EP; Sarah Cannon Research Institute, Nashville, USA; Tennessee Oncology, Nashville, USA., Hasan J; The Christie Hospital, Manchester, UK., Leary A; Gustave Roussy Cancer Centre, Paris, France., Moore KN; University of Oklahoma Health Sciences Center, Oklahoma City, USA., Mackowiak-Matejczyk B; Bialystok Oncology Center, Bialystok, Poland., Pikiel J; Regional Center of Oncology, Gdańsk, Poland., Ray-Coquard I; Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes, Lyon, France., Trask P; Genentech, Inc., South San Francisco, USA., Lin K; Genentech, Inc., South San Francisco, USA., Schuth E; Genentech, Inc., South San Francisco, USA., Vaze A; Genentech, Inc., South San Francisco, USA., Choi Y; Genentech, Inc., South San Francisco, USA., Marsters JC; Genentech, Inc., South San Francisco, USA., Maslyar DJ; Genentech, Inc., South San Francisco, USA., Lemahieu V; Genentech, Inc., South San Francisco, USA., Wang Y; Genentech, Inc., South San Francisco, USA., Humke EW; Genentech, Inc., South San Francisco, USA., Liu JF; Harvard Medical School, Boston, USA; Gynecologic Oncology Program, Dana-Farber Cancer Institute, Boston, USA. Electronic address: joyce_liu@dfci.harvard.edu.
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2018 Apr 01; Vol. 29 (4), pp. 917-923.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 29401246
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Banerjee+S%22">Banerjee S</searchLink>; Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer Research, London, UK.<br /><searchLink fieldCode="AU" term="%22Oza+AM%22">Oza AM</searchLink>; Princess Margaret Hospital, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Birrer+MJ%22">Birrer MJ</searchLink>; Massachusetts General Hospital, Boston, USA; Harvard Medical School, Boston, USA.<br /><searchLink fieldCode="AU" term="%22Hamilton+EP%22">Hamilton EP</searchLink>; Sarah Cannon Research Institute, Nashville, USA; Tennessee Oncology, Nashville, USA.<br /><searchLink fieldCode="AU" term="%22Hasan+J%22">Hasan J</searchLink>; The Christie Hospital, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Leary+A%22">Leary A</searchLink>; Gustave Roussy Cancer Centre, Paris, France.<br /><searchLink fieldCode="AU" term="%22Moore+KN%22">Moore KN</searchLink>; University of Oklahoma Health Sciences Center, Oklahoma City, USA.<br /><searchLink fieldCode="AU" term="%22Mackowiak-Matejczyk+B%22">Mackowiak-Matejczyk B</searchLink>; Bialystok Oncology Center, Bialystok, Poland.<br /><searchLink fieldCode="AU" term="%22Pikiel+J%22">Pikiel J</searchLink>; Regional Center of Oncology, Gdańsk, Poland.<br /><searchLink fieldCode="AU" term="%22Ray-Coquard+I%22">Ray-Coquard I</searchLink>; Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes, Lyon, France.<br /><searchLink fieldCode="AU" term="%22Trask+P%22">Trask P</searchLink>; Genentech, Inc., South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Lin+K%22">Lin K</searchLink>; Genentech, Inc., South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Schuth+E%22">Schuth E</searchLink>; Genentech, Inc., South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Vaze+A%22">Vaze A</searchLink>; Genentech, Inc., South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Choi+Y%22">Choi Y</searchLink>; Genentech, Inc., South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Marsters+JC%22">Marsters JC</searchLink>; Genentech, Inc., South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Maslyar+DJ%22">Maslyar DJ</searchLink>; Genentech, Inc., South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Lemahieu+V%22">Lemahieu V</searchLink>; Genentech, Inc., South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Wang+Y%22">Wang Y</searchLink>; Genentech, Inc., South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Humke+EW%22">Humke EW</searchLink>; Genentech, Inc., South San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Liu+JF%22">Liu JF</searchLink>; Harvard Medical School, Boston, USA; Gynecologic Oncology Program, Dana-Farber Cancer Institute, Boston, USA. Electronic address: joyce_liu@dfci.harvard.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007735%22">Annals of oncology : official journal of the European Society for Medical Oncology</searchLink> [Ann Oncol] 2018 Apr 01; Vol. 29 (4), pp. 917-923.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9007735 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1569-8041 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209237534%22">09237534 </searchLink><i>NLM ISO Abbreviation: </i>Ann Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29401246
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/annonc/mdy023
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 917
    Titles:
      – TitleFull: Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Banerjee S
      – PersonEntity:
          Name:
            NameFull: Oza AM
      – PersonEntity:
          Name:
            NameFull: Birrer MJ
      – PersonEntity:
          Name:
            NameFull: Hamilton EP
      – PersonEntity:
          Name:
            NameFull: Hasan J
      – PersonEntity:
          Name:
            NameFull: Leary A
      – PersonEntity:
          Name:
            NameFull: Moore KN
      – PersonEntity:
          Name:
            NameFull: Mackowiak-Matejczyk B
      – PersonEntity:
          Name:
            NameFull: Pikiel J
      – PersonEntity:
          Name:
            NameFull: Ray-Coquard I
      – PersonEntity:
          Name:
            NameFull: Trask P
      – PersonEntity:
          Name:
            NameFull: Lin K
      – PersonEntity:
          Name:
            NameFull: Schuth E
      – PersonEntity:
          Name:
            NameFull: Vaze A
      – PersonEntity:
          Name:
            NameFull: Choi Y
      – PersonEntity:
          Name:
            NameFull: Marsters JC
      – PersonEntity:
          Name:
            NameFull: Maslyar DJ
      – PersonEntity:
          Name:
            NameFull: Lemahieu V
      – PersonEntity:
          Name:
            NameFull: Wang Y
      – PersonEntity:
          Name:
            NameFull: Humke EW
      – PersonEntity:
          Name:
            NameFull: Liu JF
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 04
              Text: 2018 Apr 01
              Type: published
              Y: 2018
          Identifiers:
            – Type: issn-electronic
              Value: 1569-8041
          Numbering:
            – Type: volume
              Value: 29
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Annals of oncology : official journal of the European Society for Medical Oncology
              Type: main
ResultId 1